Interview with Drs. Robert Kocher and Bryan Roberts on a proposal for changes to the drug development and approval processes. (13:37)Download More than half of the 139 drugs approved by the FDA since 2009 are for orphan diseases and cancers. By addressing economic and business factors that play a role in this disproportion, we can work to avoid systematically underinvesting in drugs in other key areas of medicine.
No takes yet. Share an insight, caveat, or question.
Köcher et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: